Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-5.53 Insider Own14.03% Shs Outstand53.20M Perf Week7.91%
Market Cap1.30B Forward P/E- EPS next Y-7.24 Insider Trans-0.02% Shs Float47.31M Perf Month47.68%
Income-295.40M PEG- EPS next Q-1.29 Inst Own86.20% Short Float / Ratio4.53% / 4.18 Perf Quarter-15.26%
Sales159.60M P/S8.14 EPS this Y1.35% Inst Trans-1.42% Short Interest2.14M Perf Half Y1.59%
Book/sh8.31 P/B2.84 EPS next Y-38.28% ROA-24.69% Target Price57.28 Perf Year-42.50%
Cash/sh18.24 P/C1.29 EPS next 5Y- ROE-54.77% 52W Range13.57 - 42.52 Perf YTD-31.01%
Dividend- P/FCF- EPS past 5Y-42.94% ROI-64.34% 52W High-44.50% Beta1.94
Dividend %- Quick Ratio3.26 Sales past 5Y106.15% Gross Margin95.55% 52W Low73.91% ATR1.64
Employees415 Current Ratio3.26 Sales Q/Q14.19% Oper. Margin-195.24% RSI (14)62.42 Volatility9.46% 8.37%
OptionableYes Debt/Eq0.01 EPS Q/Q4.93% Profit Margin-185.09% Rel Volume1.60 Prev Close21.97
ShortableYes LT Debt/Eq0.00 EarningsNov 07 BMO Payout- Avg Volume512.67K Price23.60
Recom1.40 SMA2019.54% SMA5027.40% SMA200-3.22% Volume820,635 Change7.42%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Upgrade Guggenheim Neutral → Buy
Oct-23-23Upgrade Wedbush Neutral → Outperform $27 → $24
Jun-26-23Resumed Oppenheimer Outperform $95
Jan-12-23Downgrade Guggenheim Buy → Neutral
Jan-03-23Downgrade Wells Fargo Overweight → Equal Weight $83 → $49
Sep-09-22Initiated Barclays Overweight $90
Jun-21-22Initiated Jefferies Hold $42
May-09-22Downgrade Wedbush Outperform → Neutral
Apr-28-22Initiated Credit Suisse Outperform $104
Apr-06-22Initiated Morgan Stanley Equal-Weight $65
Dec-01-23 09:55AM
Nov-28-23 05:05PM
Nov-27-23 07:00AM
Nov-15-23 09:55AM
Nov-13-23 09:55AM
08:02AM Loading…
Nov-07-23 08:02AM
Nov-02-23 07:00AM
Oct-31-23 07:39AM
Oct-22-23 07:00AM
Oct-18-23 07:00AM
Oct-15-23 06:07PM
Sep-01-23 07:00AM
Aug-16-23 10:54AM
07:06AM Loading…
Aug-10-23 07:06AM
Aug-08-23 09:05AM
Jul-31-23 04:30PM
Jul-06-23 09:00AM
Jun-28-23 08:29PM
Jun-17-23 08:57AM
Jun-15-23 04:30PM
Jun-13-23 04:51AM
Jun-08-23 01:05PM
Jun-05-23 07:00AM
May-08-23 07:00AM
May-07-23 08:04AM
08:35AM Loading…
May-05-23 08:35AM
May-03-23 07:00AM
May-02-23 01:00PM
Apr-21-23 04:00PM
Apr-17-23 08:01AM
Apr-14-23 03:32AM
Apr-03-23 07:00AM
Feb-27-23 04:00PM
Feb-24-23 05:10AM
Feb-23-23 08:45AM
Feb-06-23 04:30PM
Jan-28-23 01:30PM
Jan-11-23 08:35AM
Jan-04-23 07:00AM
Jan-03-23 07:11AM
Dec-16-22 09:00AM
Nov-25-22 04:04AM
Nov-22-22 11:20AM
Nov-08-22 08:15AM
Nov-01-22 04:00PM
Oct-27-22 11:04AM
Oct-03-22 07:00AM
Sep-30-22 09:00AM
Sep-26-22 07:00AM
Sep-13-22 10:17AM
Aug-31-22 07:00AM
Aug-18-22 04:01PM
Aug-15-22 09:13AM
Aug-04-22 08:35AM
Aug-01-22 07:00AM
Jul-27-22 07:12AM
Jul-06-22 04:10PM
Jun-27-22 08:52AM
Jun-02-22 04:00PM
Jun-01-22 08:00AM
May-10-22 08:26AM
May-09-22 10:00AM
May-05-22 08:15AM
May-03-22 07:00AM
Apr-26-22 03:01PM
Mar-04-22 07:00AM
Mar-02-22 11:22AM
Feb-28-22 08:25AM
Feb-25-22 10:14AM
Feb-24-22 10:15AM
Feb-17-22 08:00AM
Feb-15-22 12:50PM
Feb-14-22 06:04PM
Feb-03-22 04:30PM
Jan-31-22 09:04AM
Jan-06-22 05:38PM
Dec-13-21 04:38PM
Dec-12-21 11:00AM
Dec-10-21 10:40AM
Nov-19-21 09:55AM
Nov-18-21 10:28AM
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Peck RonaldChief Medical OfficerAug 11Sale24.391,32432,28929,965Aug 14 05:27 PM
Houston John GPresident and CEOMar 01Sale29.535,878173,577917,427Mar 03 09:50 PM
Cassidy Sean AChief Financial OfficerMar 01Sale29.531,74551,530183,618Mar 03 09:49 PM
Taylor IanChief Scientific OfficerMar 01Sale29.531,05131,036101,721Mar 03 09:51 PM